* Corona Illustration by Alissa Eckert, MS; Dan Higgins, MAMS (CDC)
Fighting-off Coronavirus (SARS-CoV-2) with broad-spectrum antivirals
and establishing a preclinical viral challenge model!
Objectives of proposal: Our consortium “Fight-nCoV” will accelerate preclinical development of new broad-spectrum antivirals for inhalation, building on breath-taking ongoing research. We will determine and characterize the antiviral activity and safety of three viral entry inhibitors (Oligonucleotide, Macro-I, Tweezer) against SARS-CoV-2 in vitro and in vivo. To enable this, we will build capacity for evaluation of antiviral efficacy against SARS-CoV-2 in vitro using viral pseudotypes and wild-type SARS-CoV-2 as well as in vivo in non-human primates. Safety studies will be performed according to OECD GLP guidelines.
Expected results: We will establish a SARS-CoV-2 spike pseudotype system allowing a standardized high throughput evaluation of the antiviral activity of candidate drugs. We will have determined the antiviral efficacy of three novel broad-spectrum viral entry inhibitors: oligonucleotide, macromolecular polymers, and molecular tweezers. We will also build capacity for innovation and preclinical evaluation of our broad-spectrum antivirals and vaccines against SARS-CoV-2 by establishing a macaque challenge model. “Fight-nCoV” will provide efficacy data of our drug candidates given intranasally in non-human primates challenged with SARS-CoV-2, enable an early and valuable outcome for stakeholders and the civil society.